On Thursday, Shares of RXi Pharmaceuticals Corporation (NASDAQ:RXII), declined -0.74% to $0.5360.
RXi Pharmaceuticals Corporation, declared that results from a blinded panel and an Investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as contrast to control incision sites in the same subjects, three months post scar revision surgery.
In the first two arms of this ongoing Phase 2a study, subjects were given six intradermal injections of RXI-109, either at 5 mg/cm or 10 mg/cm, starting two weeks after scar revision surgery, with the last of the six doses administered three months post revision surgery. Subjects had one portion of the revised scar treated with RXI-109, whereas another part of the scar was revised but left untreated. This 3-month analysis comprised 16 subjects of which 15 were evaluable and 1 was lost to follow-up. Of those 15 subjects, eight were treated with 5 mg/cm of RXI-109 and seven were treated with 10 mg/cm of RXI-109. All subjects were assessed using four different evaluation methods:
POSAS (Physician and Observer Scar Assessment Scale): A compiled score based on investigator assessments of factors contributing to scar quality. These scores are offered by the investigators for both the treated and the untreated portion of the scar of their individual subjects in person;
- VAS (Visual Analogue Scale): A score based on a 10 point scale ranging from “1” (fine line scar) to “10” (worst scar possible) offered by the investigators for their individual subjects;
- A blinded assessment of photographs of the revision sites for 15 subjects by Investigators in which the clinicians were asked to indicate for Scars A and B as to which is ‘better’ or ‘not different’;
- A separate assessment of photographs of the revision sites for 15 subjects by a blinded panel, separate from the Investigators, in which the panel members were asked to indicate for Scars A and B as to which is ‘better’ or ‘not different’ .
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents.
On other hand, Shares of Celgene Corporation (NASDAQ:CELG), gained 3.34% to $117.53.
Celgene Corporation, has lost -16.48% from its peak and trades at just 19.73 times forward earnings projections. The consensus price target for the stock is $148.88 a share. The 52-week range is $83.16 - $140.72. Up 29.26% over 12 months, the company has a market cap of $89.86B; its shares recently traded at around $117.53. The P/E ratio is 44.53.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID to treat multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML).
